Evotec bags a CNS pipeline in buyout deal; AMRI bets $41M on contract manufacturing;

@FierceBiotech: Gilead scrambles toward hep C cure-all with next-gen combo pill. News | Follow @FierceBiotech

@JohnCFierce: Novartis chairman vows to preserve top R&D budget in retrenchment. More | Follow @JohnCFierce

@DamianFierce: EU smiles on Lilly and Boehringer's FDA-rejected diabetes drug. Story from Friday | Follow @DamianFierce

@EmilyMFierce: Guinea confirms fever is Ebola, has killed up to 59. Story via Reuters | Follow @EmilyMFierce

> Evotec has bought up Germany's Bionamics to get its hands on some translational therapies for neurodegeneration and central nerve system disorders. Story

> Contract developer AMRI ($AMRI) is trading $41 million for Cedarburg Pharmaceuticals, which manufactures APIs for drugmakers. Item

> Alabama biotech Innovative Med Concepts is developing a novel treatment for fibromyalgia, targeting what the company's founder believes is the viral cause of the disease. Article

Medical Device News

@FierceMedDev: Who is the top med tech company in terms of revenue? Report | Follow @FierceMedDev

@MarkHFierce: Which of the big med tech manufacturers LOST revenue in 2013? Report | Follow @MarkHFierce

@MichaelGFierce: ICYMI: MedImmune inks licensing deal with Bioasis for brain delivery platform. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Alcat test uncovers food sensitivities, and could provide a "balance sheet for the body." Article | Follow @EmilyWFierce

> GE finalizes $1B Thermo Fisher Scientific deal, snatches up 3 business units. More

> South Korea targets medical device industry as its latest growth engine. Item

> St. Jude aims to jump-start the cardiac device space with new pacers and defibrillator leads. Story

Pharma News

@FiercePharma: And the top-read special report: The top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@TracyStaton: Top-read FiercePharma: Tokyo hospital exec says #Novartis employees deeply involved in leukemia-drug trial. Story | Follow @TracyStaton

@EricPFierce: The FDA says it will boost foreign plant inspections 40%, and cut them by same amount in US. More | Follow @EricPFierce

@CarlyHFierce: Novartis' vaccine unit gets a badly needed booster from the U.K. Article | Follow @CarlyHFierce

> Politicians add fuel to the firestorm over Gilead's hep C drug pricing. Story

> Cost watchdogs demand efficacy data on new Bayer cancer drugs. News

> The color purple knocks back Novartis' Advair rival in Germany. More

CRO News

> AMRI bets on manufacturing with $41M Cedarburg buyout. News

> Parexel eyes Asian trials with Singapore expansion. Story

> GVK plots a $16.5M Indian expansion as it dials up its global presence. News

> TKL cuts the ribbon on a new Phase I operation. Article

> Risk-sharing researcher Evotec buys an academic pipeline. News

> CMO Recipharm plots a $142M Swedish IPO. Brief

Biotech IT News

> NY Genome Center taps IBM's Jeopardy!-winning Watson to speed data analysis. News

> Novo Nordisk edges forward with plans to spin off its IT unit. Story

> How will Google's forays into genomics play out? Article

> J&J collaboration with San Diego Supercomputer Center speeds genome analysis. Story

> Cancer gamification project analyzes 1.5M chromosomes in one month. Story

> Merck exec: Health IT apps need more scientific rigor. Brief

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.